Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report documents a cancer survivor who experienced cyclic alopecia areata following chemotherapy, suggesting potential autoimmune changes related to the treatment.

This review discusses recent advances in understanding alopecia areata's disease mechanisms and highlights JAK molecules as promising therapeutic targets, but reports no new clinical results; controlled trials are needed.

This review discusses the role of immune cells in the pathogenesis of alopecia areata and highlights emerging immunomodulatory strategies and novel therapeutic targets aimed at offering more effective and durable treatments for this autoimmune hair loss disorder.

This study found that dermal injection of M-CSF stimulated CD11b + myeloid cells can induce alopecia areata in mice by potentially activating B lymphocytes, offering insight into the disease's pathogenesis.

In this study, researchers found that alopecia areata patients show a significant reduction in suppressive regulatory T-cells and an increase in inflammatory T-cell populations, suggesting an immunological imbalance contributing to the disease.

This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.

In this study, researchers identified optimal hair follicle and follicular unit densities for successful hair transplantation in male patients with androgenetic alopecia in China.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

In this case report, tofacitinib was associated with new hair growth on psoriasis lesions after three months of treatment.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

This study found that patients with alopecia areata had an increased risk of mortality from self-harm, psychiatric diseases, and lung cancer compared to the general population.

In this randomized double-blind study, 160 adults with alopecia areata showed significant improvements in hair loss severity after using a bioactive peptide cosmetic product that mimics platelet-rich plasma, while the placebo group showed no significant change, underlining the treatment's potential effectiveness.

This study reviews the epidemiology of alopecia areata in the UK, focusing on its links to mental health comorbidities, autoimmune/atopic associations, and common infection incidences.

This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.

This study confirmed that the Alopecia Areata-Investigator Global Assessment and other clinical outcome assessments are valid and relevant measures of treatment success for alopecia areata patients in Japan, aligning with previous North American findings.

This study found that trichoscopy is essential for evaluating the severity of alopecia areata and predicting treatment responses, contributing to more personalized patient management.

This review of real-world treatment options for AA indicates that current therapies are insufficient, with high dissatisfaction rates, highlighting a need for improved solutions.

This study observed that an 8-session mindfulness-based cognitive therapy reduced social anxiety and improved wellbeing in some individuals with alopecia areata, though effectiveness may depend on regular mindfulness practice.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.

This genome-wide association study identified several genetic markers, including specific SNPs and HLA genotypes, associated with alopecia areata susceptibility in the Taiwanese population, highlighting key pathways involved in immune response and offering insights into the genetic origins of this autoimmune condition.

In this study, Canadian patients with alopecia areata and their caregivers reported a significant negative impact on their quality of life, including high feelings of self-consciousness, anxiety, and risk of adjustment disorder.

This study found significantly higher levels of Toll-Like Receptor 4, interferon gamma, and interleukin-17 in Iraqi patients with alopecia areata compared to controls, suggesting these immune markers play a crucial role in the disease's development and could be targets for future treatments.

This study found a significant positive association between higher air quality index values and the incidence of alopecia areata, with a clear dose-response relationship observed among the participants.

This study reviewed the burden of alopecia areata in the UAE, noting limited regional data on patient demographics and treatments but highlighting the approval and promising results of the Janus kinase inhibitor baricitinib for managing this condition.

This study found that patients with alopecia areata had significantly higher serum T3 and cortisol levels compared to healthy controls, although both remained within normal ranges, highlighting potential hormonal involvement in the condition. However, no significant differences were observed in T4 and TSH levels.

This study found that the Polish version of the AA-QLI questionnaire is a reliable and internally consistent tool for assessing health-related quality of life in Polish-speaking patients with alopecia areata.

In this study, researchers observed that individuals with alopecia areata exhibited significant changes in scalp microbiota diversity and composition, which were linked to disease severity and inflammation markers, though it remains unclear if these microbial shifts are a cause or a result of hair loss.

This study found that switching patients with alopecia areata unresponsive to topical clobetasol 17 propionate 0.05% to anthralin treatment led to improved treatment success.